DUBLIN, Calif., Sept. 18, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that members of the Astex management team will participate as presenters on oncology panels at two upcoming investor conferences.
Michael V. McCullar, PhD, MBA, senior vice president, business development, will take part in a panel discussion titled, "Targeted Oncology - Changing Cancer Therapy, Again" on Monday, September 24th at 1:00 pm ET at the Noble Financial Capital Markets Life Sciences Exposition in Stamford, Connecticut.
The following week, Harren Jhoti, PhD, president and director, will participate on a panel titled "Oncology Business Models" on Monday, October 1st at 3:15 pm CET at the Sachs Associates Biotech in Europe Investor Forum in Zurich, Switzerland. Just prior to the panel, Dr. Jhoti will deliver the Astex Pharmaceuticals corporate presentation for Forum attendees at 12 noon CET.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273